Integrum
Integrum AB is a Swedish public medical-technology company that develops FDA-approved, bone-anchored prosthetic systems (the OPRA Implant System) for amputees, selling directly to a global network of certified Centers of Excellence and serving both military and civilian patients.
- Company typePublic
- Founded1999
- HeadquartersMölndal, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Integrum does
Integrum AB is a Swedish, publicly traded medical technology company (Nasdaq First North Growth Market, ticker INTEG B) that develops and commercializes bone-anchored prosthetic systems based on osseointegration, in which a titanium implant integrates directly with the patient's residual bone to attach a prosthetic limb without a socket. The company's flagship product, the OPRA Implant System — comprising a Fixture (titanium implant), an Abutment (skin-penetrating connector) and an Abutment Screw — incorporates the proprietary BioHelix surface technology and BondedMatrix biological barrier. OPRA received CE marking in 2000 and FDA Premarket Approval in 2020, making Integrum the only company with an FDA-approved bone-anchored prosthesis system for amputees in the United States.
The business monetizes primarily through hardware sales of the OPRA implant kits and ancillary surgical instruments to certified Centers of Excellence and hospitals, complemented by surgeon training and professional services. Distribution is direct to ~50+ medical centers globally — including Johns Hopkins, Walter Reed, Shirley Ryan AbilityLab, Cedars-Sinai, UCLA, and Mayo Clinic — with anchor contracts such as a 2018 SEK 60M (five-year) frame agreement with the US Department of Defense. The next-generation e-OPRA platform, which combines osseointegration with targeted muscle reinnervation (TMR) and neural signal decoding for intuitive prosthetic control, is currently in clinical trials in the US, and a new subsidiary called Afyri was spun out in 2026 to commercialize AI-based bionic interface technology.
Following 2025 leadership changes (new CEO Martin Hillsten) and an October 2025 restructuring that eliminated six Swedish roles, Integrum is positioning itself as a streamlined, commercially focused organization scaling US sales via a new patient portal with integrated CRM. Geographic expansion is underway into Ukraine (national osseointegration pilot announced 2026) and beyond the existing footprint in Western Europe, North America, Australia, the Middle East, and South America. The company reports persistent operating losses (Q4 EBIT approximately -SEK 20M, ~-SEK 5M adjusted) and continues to finance commercial scaling through equity issuance and bridge loans.
Integrum firmographics
Firmographics- Name
- Integrum
- Legal name
- Integrum AB
- Website
- https://integrum.se
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Integrum AB is a Swedish public medical-technology company that develops FDA-approved, bone-anchored prosthetic systems (the OPRA Implant System) for amputees, selling directly to a global network of certified Centers of Excellence and serving both military and civilian patients.
- Ownership category
- akta.pro rank
Integrum industry classification
Industry- Product category
- Orthopedic Implant Systems
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets) (HLAHAMAD)
- akta.pro secondary industry
- Prosthetics/Orthotics Rehab & Amputee Rehabilitation (HSADAIAN)
Keywords
Where Integrum is headquartered
LocationHeadquarters
- HQ city
- Mölndal
- HQ country
- Sweden
- HQ region
- Europe
Offices3 records
Markets served
Integrum business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- OPRA Implant System Sales: Sale of bone-anchored prosthetic implant systems to medical centers and hospitals. Revenue generated from surgical implants performed at certified Centers of Excellence worldwide.
- Surgical Instruments and Components: Sale of specialized components and surgical instruments tailored to different indication levels for both upper and lower limb applications.
- Professional Services and Training: Training and support services for surgeons performing OPRA implant surgeries at medical centers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical device pricing negotiated with healthcare institutions |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Integrum product offering
Product offeringCore offering
Integrum develops, manufactures, and sells the OPRA Implant System, a bone-anchored prosthesis system that uses osseointegration technology to attach prosthetic limbs directly to the patient's skeleton, eliminating the need for conventional socket prostheses. The system includes the FDA-approved (PMA, 2020) and CE-marked OPRA Implant System for transfemoral amputees, the investigational e-OPRA Implant System combining osseointegration with neural interfaces for above-elbow amputees, proprietary BioHelix surface technology, and the BondedMatrix biological barrier. The company distributes through a global network of certified Centers of Excellence and provides surgical training and rehabilitation support.
Product overview
Integrum offers a portfolio of bone-anchored prosthetic systems centered on the OPRA™ Implant System, a FDA-approved (2020) and CE-marked medical device enabling direct skeletal attachment of prosthetics without socket-based solutions. The portfolio includes the core OPRA™ system (with BioHelix™ surface and BondedMatrix™ technology), the investigational e-OPRA™ system combining osseointegration with neural interfaces for enhanced prosthetic control, and the Axor connection device for lower limbs. The company operates through subsidiary Afyri for AI/bionics development and offers a patient-facing digital portal integrated with CRM systems for sales process management.
Differentiator
Problem solved
Functional benefit
Brands
- Afyri: Subsidiary focused on bionics, e-OPRA technology, and AI-based platform for the interface between human and prosthesis.
- OPRA Implant System
- BioHelix
- e-OPRA Implant System
Products and services
- OPRA Implant System FDA-approved and CE-marked bone-anchored prosthesis system enabling direct skeletal attachment of prosthetic limbs. Consists of a titanium Fixture implanted into the bone, a skin-penetrating Abutment, and an Abutment Screw, using BioHelix surface technology and BondedMatrix barrier. Sold to certified medical centers performing OPRA surgeries for transfemoral amputees.
- e-OPRA Implant System Next-generation bone-anchored prosthetic system combining osseointegration with targeted muscle reinnervation (TMR) and neural interfaces for intuitive prosthetic control. Currently in clinical trials for above-elbow amputees.
- BioHelix Surface Technology Proprietary titanium implant surface technology that promotes faster, stronger bone attachment and increases strength of the bone-to-implant interface. Licensed as part of the OPRA Implant System offering.
- BondedMatrix Biological Barrier Biologically integrated barrier forming at the skin-bone interface at the penetration site following healing. Unique to Integrum's surgical technique.
- Axor Connection Device Connection device for the OPRA Implant System tailored to lower limb applications.
- Patient Portal with CRM Integration Digital patient-facing platform supporting patient identification, communication with patients and families, tracking patient inquiries, and guiding patients through the healthcare process from initial contact to implantation.
Quantifiable outcome
- 92% success rate at 2-year follow-up
- +3 more outcomes
Companies that use Integrum
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles4 records
Integrum technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Integrum partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Shirley Ryan AbilityLabcoreLeading US rehabilitation hospital conducting first-ever home trial combining osseointegration and targeted muscle reinnervation (TMR) for above-elbow amputees using Integrum's e-OPRA implant system. The five-year clinical study is supported by NIH grant of USD 8.7 million to Shirley Ryan AbilityLab. Eight participants enrolled to test bionic arm control through bone-anchored implants, nerve rewiring, and internal sensors.
- Ukrainian Government Healthcare SystemcoreUkrainian government published draft decision for nationwide osseointegration pilot project. Two-year pilot covering full clinical pathway including surgery reimbursement, rehabilitation, implant system financing, and long-term follow-up. Muscle and nerve interface technologies referenced in infrastructure planning.
- US Department of DefensecoreFrame agreement worth SEK 60 million over five years signed with US Department of Defense. Integrum participates in research programs with the Regenerative Medicine Department at Naval Medical Research Center, Walter Reed National Military Medical Center for bone-anchored prostheses for military amputees.
- University of GothenburgcoreCollaboration with Department of Biomaterials at University of Gothenburg for development of BioHelix surface technology. Also involved in research with UCSF where Professor Rickard Brånemark serves as visiting professor.
- AfyricoreNew subsidiary being established to unlock potential within e-OPRA and create an AI-based platform for the interface between human and prosthesis. This subsidiary will accelerate development within bionics.
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
Integrum competitors and assessment
Company assessmentDirect peers
- Ottobock: Global leader in prosthetics and orthotics with a competing bone-anchored/percutaneous osseointegration prosthetic solution (Intuitive EO). Direct head-to-head competitor in the same product category serving amputee patients with similar osseointegration-based approach.
- Össur: Major prosthetics manufacturer offering socket-based and bionic limb solutions for lower and upper extremity amputees. Comparable as it serves the same amputee patient population with prosthetic devices, though focused on socket-based versus bone-anchored approaches.
- Stanmore Implants (Stryker): Now part of Stryker, Stanmore developed the STIMULITE and ITAP bone-anchored prosthetic systems. Directly competes with Integrum in osseointegration-based limb restoration for amputee patients.
Broad incumbents
- Hanger Clinic: Largest US provider of prosthetic and orthotic patient care services, including fitting and clinical support for osseointegration candidates. Comparable as it serves the same amputee patient flow, though focused on clinical services rather than the implant device itself.
- DJO (Enovis): Broad orthopedic and rehabilitation device manufacturer with prosthetic and bracing products serving amputee populations. Comparable as an adjacent medtech player in orthopedic and rehabilitation devices, though with a much broader portfolio beyond osseointegration.
- Zimmer Biomet: Global orthopedic implant leader spanning joint reconstruction, trauma, and surgical specialties. Comparable as a major medtech incumbent with the scale and orthopedic salesforce to enter bone-anchored prosthetics if the category scales.
- Stryker: Major orthopedic medical device company with a dedicated orthopedic implants and surgical equipment portfolio, including the Stanmore bone-anchored prosthetic line. Comparable as a large incumbent with overlapping orthopedic focus and existing osseointegration product line.
- Smith+Nephew: Global medical device company active in orthopedic reconstruction, sports medicine, and wound management. Comparable as a broad orthopedic incumbent with the channel and capital to compete in adjacent implant categories.
- Orthofix Medical: Spinal and orthopedic implant company with biologics and limb reconstruction products. Comparable as a focused orthopedic implant peer serving surgeons and hospitals, though with a different core portfolio (spine, bone growth stimulation).
Emerging players
- Exactech: Smaller orthopedic implant company focused on joint replacement and extremity solutions. Comparable as a similarly-sized orthopedic implant player in adjacent reconstructive categories, with potential overlap if Integrum expands beyond amputee-specific indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Integrum social profiles
Digital presenceIntegrum compliance and trust
Trust signalCompliance2 records
Integrum financial estimates
Financial estimateRevenue estimate
Valuation estimate
Integrum leadership team
Management profileNumber of profiles
Profiles10 records
Integrum subsidiaries and ownership
Company hierarchySubsidiaries1 record
Integrum funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Integrum M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Integrum
What does Integrum do?
Integrum develops, manufactures, and sells the OPRA Implant System, a bone-anchored prosthesis system that uses osseointegration technology to attach prosthetic limbs directly to the patient's skeleton, eliminating the need for conventional socket prostheses. The system includes the FDA-approved (PMA, 2020) and CE-marked OPRA Implant System for transfemoral amputees, the investigational e-OPRA Implant System combining osseointegration with neural interfaces for above-elbow amputees, proprietary BioHelix surface technology, and the BondedMatrix biological barrier. The company distributes through a global network of certified Centers of Excellence and provides surgical training and rehabilitation support.
Is Integrum a public or private company?
Integrum is a public company. It is classified as public and is currently operating.
When was Integrum founded?
Integrum was founded in 1999. It employs 11 to 50 people.
Where is Integrum based?
Integrum is headquartered in Mölndal, Sweden, in the Europe region.
How does Integrum make money?
Three revenue lines are on record. OPRA Implant System Sales are the primary driver. The others are surgical Instruments and Components and professional Services and Training.
Who are Integrum's main competitors?
Direct peers on record are Ottobock, Össur and Stanmore Implants (Stryker). Broad incumbents are Hanger Clinic, DJO (Enovis), Zimmer Biomet, Stryker, Smith+Nephew and Orthofix Medical. Exactech is listed as an emerging player.
Does Integrum have an API?
No public API is recorded for Integrum.
What industry is Integrum in?
Integrum's product category is Orthopedic Implant Systems. Its primary akta.pro industry code is HLAHAMAD, Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets), with a secondary code of HSADAIAN, Prosthetics/Orthotics Rehab & Amputee Rehabilitation. Its NAICS code is 339113 and its SIC code is 3842.